Hylon Plus Injection (Sodium Hyaluronate)

Adult administration

Typically, 1 injection once a week for 3 weeks is administered into the intra-articular space of the knee or shoulder, but the frequency of administration can be adjusted according to symptoms.

This medication contains sodium hyaluronate and is injected into the joint. First, it should never be administered to patients who have previously shown allergic reactions to its components. Caution is also advised when using this medication in patients who have had allergic reactions to other medications, altered liver function, or a history of liver disease. If there are skin diseases or infections at the site of the joint injection, the condition should be carefully examined before administration. Severe shock reactions may occur rarely while using this medication, so the patient's condition must be closely monitored after injection. Allergic symptoms may include swelling or redness around the face or eyes, rash, hives, and itching, and if these symptoms occur, administration should be immediately stopped, and treatment should be initiated. Temporary pain, swelling, redness, warmth, and pressure may occur at the injection site, so these symptoms should also be carefully observed. Nausea, vomiting, and fever may occasionally occur, so it is important to report any unusual symptoms. If severe inflammation occurs due to advanced osteoarthritis, it is advisable to first reduce the inflammation before using this medication. After administration, stabilizing the injection site to reduce local pain is recommended. It is important to inject this medication precisely into the joint, as leakage outside the joint may cause pain. The injection should be performed in a sterile condition, and if symptoms do not improve, administration should be stopped after three injections. If there is fluid accumulation in the joint, it is advisable to aspirate as needed before administration. This medication is not suitable for intravenous injection or for use in the eyes. When injecting, it is advisable to use a syringe needle of gauge 22-23. Additionally, caution should be taken as the medication may precipitate if used in conjunction with disinfectants like benzalkonium chloride or chlorhexidine. Women who are pregnant or may become pregnant should use this medication cautiously, as its safety has not been established, and only if the benefits outweigh the risks. It is advisable to avoid breastfeeding while using this medication, as it may be transmitted through breast milk. The safety of this medication in children has not been adequately established, so it should be used carefully only when necessary. Elderly patients may have reduced physical function, so caution is required when administering.

Serious side effects

Shock symptoms (severe allergic reactions) may occur, and if symptoms arise, administration should be stopped, and appropriate treatment should be provided.

Mild side effects

Edema (facial, periorbital, etc.) due to hypersensitivity, facial flushing, rash, hives, and itching may occur. Pain, swelling, effusion, redness, warmth, and severe local pressure may be observed at the joint injection site. Nausea, vomiting, and fever may occur.

This medication should be stored in a sealed container to prevent exposure to air, and it is important to keep it at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication and prevent deterioration.

Appearance

An injection filled with a colorless, transparent, viscous liquid contained in a colorless and transparent glass tube sealed with rubber stoppers at both ends (a part of the pre-filled syringe system).

Package unit

2ml/pre-filled syringe x 3